In addition to suppressing the elevated GH and IGF-1 levels and controlling the signs and symptoms of the disease, octreotide LAR treatment led to a clear regression of tumour volumes (i.e. > 20% reduction from initial volume) in all the patients with microadenoma and in approximately 70% of those with macroadenoma. This evidence concerns the gene IGF1 and neoplasm.